NAD+ Precursors and Longevity: What the Human Trials Show

Why NAD+ became the center of the longevity conversation

Nicotinamide adenine dinucleotide — NAD⁺, chemical formula C₂₁H₂₇N₇O₁₄P₂ — is one of the most heavily used molecules in your biochemistry. It is the electron carrier that lets mitochondria turn food into ATP, and it is the required fuel for two families of repair and signalling enzymes, the sirtuins and the PARPs, that sit at the heart of most theories of aging. When NAD⁺ runs low, energy metabolism and DNA repair both suffer at once.

The observation that launched an industry is simple: tissue NAD⁺ levels decline substantially with age across many species. If a longevity-relevant coenzyme drains as we get older, the intuitive fix is to top it back up. You cannot usefully swallow NAD⁺ itself — it is too large and unstable to survive digestion intact — so the strategy is to supply a precursor, a smaller building block the body converts into NAD⁺. That is what NMN and NR are.

NMN, NR and the difference that mostly isn't

Two precursors dominate the market. Nicotinamide riboside (NR), a cation with formula C₁₁H₁₅N₂O₅⁺, is one enzymatic step further from NAD⁺. Nicotinamide mononucleotide (NMN), formula C₁₁H₁₅N₂O₈P, is NR with a phosphate group attached and sits one step closer. Marketing has spilled a great deal of ink on which is "better," usually on theoretical grounds about which enters cells more directly.

The human data deflate that debate. Both raise NAD⁺, and until recently no trial had compared them head to head in people. That gap was filled in January 2026, and the answer — as we will see — was that they perform comparably, and by a mechanism neither the NMN camp nor the NR camp had emphasised. The honest summary is that arguing NMN-versus-NR is arguing about the one thing both molecules are actually proven to do equally well, while the outcomes that would justify taking either remain largely unproven.

The 2026 twist: your gut bacteria do some of the work

The most important recent study is also the most surprising. According to PubMed, in a randomized, placebo-controlled trial of 65 healthy adults published in Nature Metabolism in January 2026, Christen and colleagues gave participants NR, NMN or plain nicotinamide (Nam) for 14 days. NR and NMN — but not Nam — comparably increased circulating NAD⁺. The mechanistic finding was the headline: using human microbiota fermented outside the body, the researchers showed that NR and NMN are converted by gut bacteria into nicotinic acid (a form of vitamin B3), which turns out to be a far more potent NAD⁺ booster in whole blood than the precursors themselves.^[1]

In other words, part of what you get from an expensive NMN capsule may be routed through the gut microbiome and delivered as ordinary niacin chemistry. The same study reported that NR and NMN also shifted microbial metabolism in ways that may support the gut barrier. It is a genuinely new model of how these supplements work — and a reminder that the marketing story ("NMN goes straight into your cells to become NAD⁺") was, at best, incomplete.

Where the human evidence is genuinely positive: metabolism

Raising NAD⁺ is not the goal; changing health is. On that front the single most rigorous positive result comes from metabolism. According to PubMed, in a 10-week randomized, double-blind, placebo-controlled trial in Science in 2021, Yoshino and colleagues gave 250 mg/day of NMN to postmenopausal women with prediabetes who were overweight or obese. Using the hyperinsulinemic-euglycemic clamp — the gold-standard method for measuring insulin action — they found that NMN significantly increased muscle insulin sensitivity and insulin signalling, effects not seen with placebo.^[2] This is the trial most often cited as proof that NMN "works," and on its narrow endpoint it is a well-designed, credible result.

A pharmaceutical-grade NMN formulation adds a second, cardiometabolic signal. According to PubMed, in a 28-day randomized trial in The Journal of Clinical Endocrinology & Metabolism in 2023 — a study whose authors include David Sinclair and Shalender Bhasin — overweight and older adults taking the βNMN drug candidate MIB-626 saw substantial dose-related rises in NAD⁺ alongside significant reductions in total and LDL cholesterol, body weight and diastolic blood pressure versus placebo.^[3] Encouragingly consistent — but note the caveats built into the same paper: insulin sensitivity and abdominal fat did not change, and the trial ran only four weeks.

Where it disappoints: muscle, strength and function

If NAD⁺ precursors were broadly rejuvenating, the clearest place to see it would be aging muscle — the tissue where mitochondrial decline bites hardest. The data there are deflating. According to PubMed, a 2025 systematic review and meta-analysis of randomized trials in the Journal of Cachexia, Sarcopenia and Muscle pooled the NMN and NR trials in older adults and found no significant benefit on muscle mass, handgrip strength, gait speed or the chair-stand test; the authors concluded current evidence does not support these supplements for preserving muscle in adults over 60.^[4]

The same pattern shows up inside individual trials. In the 28-day MIB-626 study above, NAD⁺ roughly doubled — yet muscle strength, fatigability, aerobic capacity and stair-climbing power were no different from placebo.^[3] Raising the coenzyme, it turns out, does not automatically translate into a stronger, faster body. For that, the interventions with hard evidence remain the boring ones: resistance training after 40 and the cardiorespiratory fitness captured by VO₂ max, both of which predict mortality far more strongly than any NAD⁺ biomarker.

Safety: the reassuring part

On tolerability, the record is good over the timescales studied. According to PubMed, in a 2018 randomized crossover trial in Nature Communications, Martens and colleagues gave 1000 mg/day of NR to healthy middle-aged and older adults and found it was well tolerated and effectively raised NAD⁺ metabolism, with a preliminary hint of reduced blood pressure and arterial stiffness that they flagged for future confirmation.^[5] Pharmacokinetic work on pharmaceutical NMN reached the same tolerability conclusion, with dose-related NAD⁺ increases and no excess of adverse events.^[6] Trials have generally run weeks to a few months, so "safe" here means short-to-medium term, not lifelong.

The honest bottom line

The most complete accounting comes from a 2026 systematic review. According to PubMed, Gallagher and Emmanuel conducted a PRISMA-guided review in Ageing Research Reviews of 113 intervention studies (33 in humans, 28 of them randomized). Their conclusion is worth quoting in spirit: oral NR and NMN consistently hit their biochemical target — they raise NAD⁺ and are generally well tolerated — but effects on functional, metabolic, vascular and other healthspan-relevant outcomes were "heterogeneous and often null or endpoint-specific," and overall clinical effectiveness for anti-aging remains inconclusive.^[7]

That is the real state of play. Three caveats deserve to be stated plainly. First, no human trial has measured lifespan or healthspan over years; every positive result is a short-term surrogate (a lab value, a clamp measurement, a lipid panel), not a demonstration of slower aging. Second, the effects that do appear are specific and modest — insulin sensitivity in one population, cholesterol in another — not the broad rejuvenation the category is sold on. Third, the regulatory ground is unstable: the U.S. FDA has taken the position that NMN is excluded from sale as a dietary supplement because it was investigated as a drug, so product availability, purity and labelling accuracy vary considerably.

NAD⁺ precursors are among the better-studied longevity supplements, and unlike much of the field they have real randomized human data and a clean short-term safety record. But "raises a biomarker that declines with age" is a hypothesis, not a benefit. This is the same discipline that separates the genuine longevity bets — fitness, muscle, sleep, and the anti-inflammatory diet that lowers inflammaging — from the mechanistically elegant compounds, like urolithin A and GlyNAC, that are still waiting for the trial that would settle them. NAD⁺ boosting sits firmly in that second group: promising, active, and unproven.